110704-48-8

Basic information

• Product Name: 5-bromo-2-(chloromethyl)-1,3-benzoxazole
• Synonyms: 5-bromo-2-(chloromethyl)-1,3-benzoxazole;5-Bromo-2-chloromethyl-benzooxazole;2-(Chloromethyl)-5-bromo-1,3-benzoxazole
• CAS NO: 110704-48-8
• Molecular Formula: C₈H₅BrClNO
• Molecular Weight: 246.4884
• Mol File: 110704-48-8.mol

Chemical Properties

• Melting Point: 68-70°
• Boiling Point: 299.4±20.0 °C(Predicted)
• Appearance: /
• Density: 1.718±0.06 g/cm3(Predicted)
• PKA: -1.07±0.10(Predicted)
• CAS DataBase Reference: 5-bromo-2-(chloromethyl)-1,3-benzoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-2-(chloromethyl)-1,3-benzoxazole(110704-48-8)
• EPA Substance Registry System: 5-bromo-2-(chloromethyl)-1,3-benzoxazole(110704-48-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 110704-48-8(Hazardous Substances Data)

Upstream product

• 40925-68-6 2-amino-4-bromo-phenol 
• 74974-54-2 2-chloro-1,1,1-trimethoxyethane 
• 36743-66-5 ethyl chloroacetimidate hydrochloride 
• 24036-48-4 2-chloro-N-(5-bromo-2-hydroxyphenyl)acetamide 

Downstream Products

• 1521138-70-4 5-bromo-2-((4-(1-(2-fluoroethyl)-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)benzo[d]oxazole 

Relevant articles and documents

COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF

The present invention provides a compound having a specific chemical structure and having PDE9A inhibitory activity, or a pharmaceutically acceptable salt thereof. The present invention provides a composition containing the compound or a pharmaceutically acceptable salt thereof. The present invention provides a pharmaceutical use, for treating or preventing PDE9A-related diseases, of the compound according to the present invention, a salt thereof, and a composition containing the compound or salt. The present invention also provides a method for treating or preventing PDE9A-related diseases, the method comprising administering an effective amount of the compound according to the present invention, a salt thereof, or a composition containing the compound or salt to a subject in need of treatment.

Anti-oligomerization sheet molecules: Design, synthesis and evaluation of inhibitory activities against α-synuclein aggregation

Aggregation of α-synuclein (α-Syn) play a key role in the development of Parkinson Disease (PD). One of the effective approaches is to stabilize the native, monomeric protein with suitable molecule ligands. We have designed and synthesized a series of sheet-like conjugated compounds which possess different skeletons and various heteroatoms in the two blocks located at both ends of linker, which have good π-electron delocalization and high ability of hydrogen-bond formation. They have shown anti-aggregation activities in vitro towards α-Syn with IC50 down to 1.09 μM. The molecule is found binding in parallel to the NACore within NAC domain of α-Syn, interfering aggregation of NAC region within different α-Syn monomer, and further inhibiting or slowing down the formation of α-Syn oligomer nuclei at lag phase. The potential inhibitor obtained by our strategy is considered to be highly efficient to inhibit α-Syn aggregation.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Process for preparing chloromethyl thiazoles or oxazoles, and intermediates for use therein

Chloromethyl group substituted heterocyclic compounds of the formulae STR1 wherein X is O or S; Y together with the two carbons to which Y is attached forms phenyl, pyridyl or pyrimidyl, each of which may be substituted by R; R is one of iodo or trifluoromethylthio or one or two of fluoro, chloro, bromo, (C1 -C4)alkyl, (C1 -C4)alkoxy, (C1 -C4)alkylthio, (C1 -C4)alkylsulfinyl, (C1 -C4)alkylsulfonyl or trifluoromethyl; and R1 is hydrogen or R, are prepared by reacting a bifunctional compound of the formulae STR2 with a 2-chloro-1,1,1-tri(C1 -C6)alkoxyethane. Most of the compounds of formulae I and II are novel. These compounds are intermediates of use in the preparation of compounds having pharmaceutical activity. The 2-chloro-1,1,1-tri(C1 -C6)alkoxyethanes are prepared from the corresponding tri(C1 -C6)alkoxyethanes by chlorination with N-chlorosuccinimide or with chlorine in pyridine and a chlorohydrocarbon cosolvent.